Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Warfarin + vitamin K refers to the interaction between the anticoagulant drug warfarin and vitamin K. Warfarin is a small molecule oral anticoagulant that acts as a vitamin K antagonist. It inhibits the enzyme vitamin K epoxide reductase complex subunit 1 (VKORC1), thereby blocking the recycling of vitamin K and reducing synthesis of active clotting factors II, VII, IX, and X as well as proteins C and S[1][3][6]. This results in decreased blood clotting ability and is used for prevention and treatment of venous thromboembolism, pulmonary embolism, atrial fibrillation-related thromboembolism, cardiac valve replacement-associated thrombosis, and post-myocardial infarction events[1][3]. Vitamin K (including forms such as phytonadione/vitamin K1 or menaquinone/vitamin K2) is an essential cofactor for γ-carboxylation of these clotting factors; supplementation with exogenous vitamin K can reverse or reduce warfarin’s anticoagulant effect by bypassing VKORC1 inhibition[6]. The balance between dietary/supplemental intake of vitamin K and warfarin dosing is critical for maintaining stable anticoagulation therapy[5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on warfarin + vitamin k.